文献速递肝病

综述:乙型肝炎感染的新型生物标志物

Review article: novel biomarkers in hepatitis B infection.
PubMed 文献 · Aliment Pharmacol Ther · 2022-06-30

本文检索PubMed 2010至2022年文献,评述qHBsAg、HBV RNA和HBcrAg等新型病毒标志物在预测治疗结局、风险分层和停药后病毒再激活中的价值,并指出检测标准化与人群多样性验证的不足。

要点

  • HBcrAg、HBV RNA和qHBsAg可能有助于预测治疗结局、分层未来并发症风险及估计停药后病毒再激活。
  • HBV RNA和HBcrAg滴度可能准确反映cccDNA转录活性,在核苷类似物治疗背景下尤其有信息价值。
  • 多数研究在白种人或亚洲人群中进行,HBV RNA检测方法缺乏标准化,且标志物可及性仍有限。

核心结论

  • 新型病毒生物标志物有潜力提供对感染自然史的额外洞察,并实现更个体化、成本效益更高的诊疗框架。
  • 但标志物可及性仍有限,需进一步努力在不同种族人群中验证其应用、确认预测性截断值,并确立其在新颖抗病毒治疗时代的作用。

研究设计与样本

  • 本文为综述,通过检索PubMed纳入2010年至2022年间发表的乙型肝炎生物标志物领域文章。

主要发现

  • HBcrAg、HBV RNA和qHBsAg等新型标志物可能有助于预测治疗结局、分层未来并发症风险及估计停药后病毒再激活。
  • HBV RNA和HBcrAg滴度可能准确反映cccDNA转录活性,在核苷类似物治疗背景下尤其有信息价值。
  • 大多数研究在白种人或亚洲人群中进行,HBV RNA检测方法缺乏标准化。

局限性

  • 大多数研究在白种人或亚洲人群中进行。
  • HBV RNA检测方法缺乏标准化。
  • 标志物可及性仍有限。
  • 需在不同种族人群中验证其应用、确认预测性截断值,并确立其在新颖抗病毒治疗时代的作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chronic hepatitis B remains a global health problem with an estimated 296 million people affected worldwide. Individuals are at risk of serious complications such as cirrhosis and hepatocellular carcinoma and accurately predicting these clinical endpoints has proven difficult. However, several viral biomarkers have recently been developed, including quantitative HBV surface antigen (qHBsAg), hepatitis B RNA (HBV RNA) and core-related antigen (HBcrAg), and shown promise in a range of clinical settings. AIMS: To critically appraise these novel biomarkers, exploring their potential uses, availability of assays and areas for future development. METHODS: We performed a literature search of PubMed, identifying articles published in the field of hepatitis B biomarkers between 2010 and 2022. RESULTS: Novel biomarkers such as HBcrAg, HBV RNA and qHBsAg may be useful in predicting treatment outcomes, stratifying the risk of future complications and estimating off-treatment viral reactivation. Furthermore, HBV RNA and HBcrAg titres may accurately reflect cccDNA transcriptional activity, and this is particularly informative in the context of nucleoside analogue therapy. On a cautionary note, most studies have been performed in Caucasian or Asian populations, and methods for detecting HBV RNA lack standardisation. CONCLUSION: Novel viral biomarkers have the potential to provide additional insights into the natural history of infection and allow a more bespoke, cost-effective framework of care. However, access remains limited, and further efforts are needed to validate their use in ethnically diverse populations, confirm predictive cut-off values, and establish their role in the era of novel antiviral therapies.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Lok J, Dusheiko G, Carey I, et al. Review article: novel biomarkers in hepatitis B infection. Aliment Pharmacol Ther. 2022. PMID: 35770458. doi:10.1111/apt.17105

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。